Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VKTX alert in real time by email

Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001)

Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p<0.05)

Up to 48% of VK2809-Treated Patients Achieved Both Resolution of NASH and a ≥1-Stage Improvement in Fibrosis as Compared to 20% for Placebo (p=0.01)

Adverse Events, Including GI-Related AEs, Similar Among VK2809-Treated Patients vs. Placebo at Week 52; Consistent with Prior Data Reported at Week 12

Conference Call Scheduled for 8:00 a.m. ET Today

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).  As previously reported, the study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.  The results announced today highlight achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks of treatment with VK2809.

Histologic Results at 52 Weeks

On the secondary endpoint of NASH resolution with no worsening of fibrosis, VK2809-treated patients demonstrated NASH resolution ranging from 63% to 75%, compared with 29% for placebo (p<0.05 for each VK2809 treatment group).  Across the combined VK2809 treatment groups, 69% achieved NASH resolution (p<0.0001 vs. placebo).  Resolution of NASH was defined as a non-alcoholic fatty liver disease activity score (NAS) of 0 or 1 for inflammation and 0 for ballooning.

On the secondary endpoint evaluating improvement in fibrosis with no worsening of NASH, VK2809-treated patients demonstrated improvement in fibrosis ranging from 44% to 57%, compared with 34% for placebo (p<0.05 for the 5 mg and 10 mg QOD cohorts).  Across the combined VK2809 treatment groups, 51% achieved improvement in fibrosis with no worsening of NASH (p=0.03 vs. placebo).  Improvement in fibrosis without worsening of NASH was defined as a ≥1-stage improvement in fibrosis and no increase in NAS for ballooning, inflammation, or steatosis.

On the secondary endpoint evaluating the proportion of patients experiencing both resolution of NASH and improvement in fibrosis, VK2809-treated patients demonstrated improvement ranging from 40% to 50%, compared with 20% for placebo (p<0.05 for the 5 mg and 10 mg QOD cohorts).  Across the combined VK2809 treatment groups, 44% achieved this endpoint (p=0.003 vs. placebo).  Resolution of NASH and improvement in fibrosis were defined as described above.



Placebo

(n = 41)

VK2809

1 mg QD

(n = 14)4,5

VK2809

2.5 mg QD

(n = 52)

VK2809

5 mg QOD

(n = 27)5

VK2809

10 mg QOD

(n = 44)

VK2809

combined

(n=137)

Resolution of

NASH with no

worsening of

fibrosis1,2

29.3 %

71.4%

(p=0.0215)6

65.4%

(p=0.0023)

63.0%

(p=0.0091)

75.0%

(p=0.0001)

68.6%

(p<0.0001)

Fibrosis

improvement of

≥ 1-stage with

no worsening of

NASH2,3

34.1 %

57.1%

(p=0.1543)

44.2%

(p=0.4414)

51.9%

(p=0.0304)

56.8%

(p=0.0497)

51.1%

(p=0.0308)

Resolution of

NASH and

≥ 1-stage

improvement in

fibrosis1,2

19.5 %

50.0%

(p=0.0856)

40.4%

(p=0.0508)

40.7%

(p=0.0206)

47.7%

(p=0.0115)

43.8%

(p=0.0032)



Notes: 1) Resolution of NASH defined as NAS inflammation score of 0-1, ballooning score of 0. 2) Includes all patients with baseline and post-baseline MRI, and Week 52 biopsy. 3) No worsening of NASH defined as no increase from baseline in ballooning, inflammation, or steatosis. 4) Reduced size cohort intended to identify a minimally effective dose. 5) Enrollment suspended at approximately 50% of target to accelerate study completion. 6) p-values vs. placebo using Cochran-Mantel-Haenszel test.

Study results were consistent under various sensitivity analyses.  A more conservative sensitivity analysis, which categorized subjects with missing data as non-responders, produced similar statistical outcomes.  These analyses demonstrate the robustness of the efficacy signal observed in this study.



Placebo

(n = 57)

VK2809

1 mg QD

(n = 17)4,5

VK2809

2.5 mg QD

(n = 59)

VK2809

5 mg QOD

(n = 36)5

VK2809

10 mg QOD

(n = 56)

VK2809

combined

(n=168)

Resolution of

NASH with no

worsening of

fibrosis, missing

data imputed as

non-response1,2

21.1 %

58.8%

(p=0.0406)6

57.6%

(p=0.0002)

47.2%

(p=0.0256)

58.9%

(p<0.0001)

56.0%

(p<0.0001)

Fibrosis

improvement of

≥ 1-stage with

no worsening of

NASH, missing

data imputed as

non-response2,3

24.6 %

47.1%

(p=0.2615)

39.0%

(p=0.0850)

38.9%

(p=0.0979)

44.6%

(p=0.0159)

41.7%

(p=0.0101)

Resolution of

NASH and

≥ 1-stage

improvement in

fibrosis, missing

data imputed as

non-response1,2

14.0 %

41.2%

(p=0.1302)

35.6%

(p=0.0072)

30.6%

(p=0.0440)

37.5%

(p=0.0034)

35.7%

(p=0.0009)



Notes: 1) Resolution of NASH defined as NAS inflammation score of 0-1, ballooning score of 0. 2) Includes all patients with baseline and post-baseline MRI, and Week 52 biopsy, with missing data imputed as non-response. 3) No worsening of NASH defined as no increase from baseline in ballooning, inflammation, or steatosis. 4) Reduced size cohort intended to identify a minimally effective dose. 5) Enrollment suspended at approximately 50% of target to accelerate study completion. 6) p-values vs. placebo using Cochran-Mantel-Haenszel test.

"These data provide compelling evidence of VK2809's efficacy in patients with biopsy-confirmed NASH and fibrosis," stated Brian Lian, Ph.D., chief executive officer of Viking.  "Treatment with VK2809 led to statistically significant improvements across key histologic endpoints, including fibrosis, which supports the value of thyroid hormone receptor beta agonism as an important mediator of disease.  Consistent with prior results, VK2809 demonstrated an excellent tolerability profile in this study, with low rates of GI disturbances and treatment related adverse events.  The VOYAGE results further indicate VK2809's best-in-class profile and we look forward to sharing the full results at a future medical meeting."

Reduction in Liver Fat Content at 52 Weeks

As reported previously, patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, which was the primary endpoint in VOYAGE.  Importantly, patients receiving VK2809 continued to demonstrate statistically significant reductions in liver fat content at Week 52, with the mean relative change from baseline ranging from 37% to 55%.  The response rate in this study, defined as the proportion of patients experiencing reduction in liver fat ≥30%, ranged from 64% to 88%, with all treatment arms demonstrating statistically significant improvement compared to placebo.



Placebo

(n = 48)

VK2809

1 mg QD

(n = 14)4,5

VK2809

2.5 mg QD

(n = 55)

VK2809

5 mg QOD

(n = 27)5

VK2809

10 mg QOD

(n = 49)

Mean baseline

liver fat content

20.4 %

21.7 %

20.3 %

18.4 %

21.5 %

Mean relative

change in liver

fat by MRI-

PDFF1,2

-12.8 %

-36.6%

(p=0.0060)

-48.3%

(p<0.0001)

-43.9%

(p<0.0001)

-55.3%

(p<0.0001)

Median relative

change in liver

fat

-9.3 %

-34.3 %

-54.2 %

-46.7 %

-56.3 %

Percentage of

patients

experiencing ≥

30% reduction

in liver fat3

27.1 %

64.3%

(p=0.0116)

78.2%

(p<0.0001)

74.1%

(p=0.0002)

87.8%

(p<0.0001)



Notes: Data from patients who received a baseline and week 52 MRI. 1) Least squares mean percent change from baseline using an Analysis of Covariance (ANCOVA) model. 2) p-value vs. placebo. 3) p-value vs. placebo using logistic regression model. 4) Reduced size cohort intended to identify a minimally effective dose. 5) Enrollment suspended at approximately 50% of target to accelerate study completion.

Reduction in Plasma Lipids at Week 52

Consistent with prior studies, patients receiving VK2809 demonstrated placebo-adjusted reductions in LDL-C ranging from 20% to 25% (p<0.01 for each arm), as well as reductions in triglycerides and atherogenic proteins such as apolipoprotein B (ApoB), lipoprotein (a) [Lp(a)], and apolipoprotein C-III (ApoC-III), all of which have been correlated with cardiovascular risk. These results support prior data demonstrating that VK2809 may offer a cardio-protective benefit through its robust reduction in plasma lipids.

Safety and Tolerability

VK2809 demonstrated encouraging safety and tolerability in this study through 52 weeks of treatment, with minimal differences compared with the previously reported results at 12 weeks.  The majority (94%) of treatment related adverse events among patients receiving VK2809 were reported as mild or moderate.  Discontinuations due to adverse events were low and balanced among placebo and treatment arms.  As we reported in the topline data release last year, one treatment-related serious adverse event (SAE) was reported in a patient receiving VK2809.  A patient with a history of psychiatric disorders reported a worsening of their symptoms.  As in prior studies, and at the 12-week timepoint in this study, VK2809 demonstrated excellent gastrointestinal (GI) tolerability throughout the 52-week treatment window in this study.  Rates of nausea, diarrhea, stool frequency, and vomiting were similar among VK2809-treated patients compared to placebo.



Placebo

(n = 65)

VK2809

1 mg QD

(n = 17)

VK2809

2.5 mg QD

(n = 66)

VK2809

5 mg QOD

(n = 37)

VK2809

10 mg QOD

(n = 61)

VK2809

combined

(n=181)

Treatment

emergent adverse

events, TEAEs

(number of

subjects, (%))

51 (78.5 %)

14 (82.4 %)

55 (83.3 %)

29 (78.4 %)

58 (95.1 %)

156 (86.2 %)

Drug-related

TEAEs1

22 (33.8 %)

7 (41.2 %)

13 (19.7 %)

9 (24.3 %)

24 (39.3 %)

53 (29.3 %)

TEAEs leading to

study

discontinuation

6 (9.2 %)

2 (11.8 %)

1 (1.5 %)

2 (5.4 %)

6 (9.8 %)

11 (6.1 %)

Drug-related GI

adverse events

12 (18.5 %)

4 (23.5 %)

3 (4.5 %)

1 (2.7 %)

7 (11.5 %)

15 (8.3 %)

    Nausea

5 (7.7 %)

2 (11.8 %)

2 (3.0 %)

1 (2.7 %)

3 (4.9 %)

8 (4.4 %)

    Diarrhea

2 (3.1 %)

3 (17.6 %)

2 (3.0 %)

1 (2.7 %)

3 (4.9 %)

9 (5.0 %)



Notes: Study safety population, defined as all patients who were randomized and received at least one dose of study drug. 1) Deemed by investigator as possibly, probably, or definitely related to study drug.

After 52 weeks, plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reduced in every treatment arm receiving VK2809 compared with patients receiving placebo, though not all treatment arms achieved statistically significant improvement vs. placebo.  Levels of thyroid hormones such as thyroid stimulating hormone (TSH), free thyroxine (fT4), and free triiodothyronine (fT3) were relatively unchanged among VK2809-treated patients compared to patients receiving placebo.  Changes in vital signs, including blood pressure, heart rate, and body weight were similar among patients receiving VK2809 as compared to patients receiving placebo.

Study Design

The VOYAGE study was a randomized, double-blind, placebo-controlled, multicenter, international trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis.  Enrollment included patients with at least 8% liver fat content as measured by MRI-PDFF, as well as F2 and F3 fibrosis.  The study allowed for up to 25% of enrolled patients to have F1 fibrosis provided they also possessed at least one additional risk factor, such as diabetes, obesity or hypertension, among others.  The primary endpoint of the study evaluated the change in liver fat content from baseline to Week 12 in patients treated with VK2809 as compared to patients receiving placebo.  Secondary objectives include the evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of treatment.

Conference Call Today at 8:00 a.m. ET

Viking will hold a conference call today at 8:00 a.m. ET to discuss the top-line results from the Phase 2b VOYAGE study of VK2809.  To participate on the conference call, please dial 844-850-0543 from the U.S. or 412-317-5199 from outside the U.S.  In addition, following the completion of the call, a telephone replay will be accessible until June 11, 2024, by dialing 877-344-7529 from the U.S. or 412-317-0088 from outside the U.S. and entering conference ID 5121997.  Those interested in listening to the conference call live via the internet may do so by visiting the Investor Relations section of Viking's website at https://ir.vikingtherapeutics.com/webcasts.  An archive of the webcast will be available for 7 days on the company's website at https://ir.vikingtherapeutics.com/webcasts.

About VK2809

VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promising therapeutic potential in a range of lipid disorders. The compound recently completed the Phase 2b VOYAGE study in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis, successfully achieving both the trial's primary and secondary endpoints. VK2809 also successfully achieved primary and secondary endpoints in a Phase 2a study for the treatment of patients with elevated LDL-C and non-alcoholic fatty liver disease (NAFLD). Selective activation of the thyroid hormone beta receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels via multiple mechanisms, including increasing the expression of genes associated with lipid metabolism and clearance.  

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. Viking is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. Viking holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.  These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.  These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-52-week-histologic-data-from-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-nash-302162714.html

SOURCE Viking Therapeutics, Inc.

Get the next $VKTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VKTX

DatePrice TargetRatingAnalyst
2/13/2025$102.00Sector Outperform
Scotiabank
2/7/2025$38.00Neutral
Citigroup
12/2/2024Overweight
Piper Sandler
11/22/2024$109.00Buy
B. Riley Securities
11/4/2024$90.00 → $102.00Buy
H.C. Wainwright
9/11/2024$80.00Overweight
JP Morgan
6/27/2024$105.00Overweight
Morgan Stanley
5/16/2024$115.00 → $116.00Outperform → Strong Buy
Raymond James
More analyst ratings

$VKTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

    13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.  VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabo

    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

    CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the sig

    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

     Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make Prepayments Totaling $150 Million Between 2025-2028 SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an

    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VKTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VKTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VKTX
SEC Filings

See more

$VKTX
Financials

Live finance-specific insights

See more
  • Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

    Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time  SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E

    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

    Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter

    $AGEN
    $LGND
    $MRK
    $TAK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$VKTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more